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To the Editor: We read with great interest the recently
published article by Esteghamati and colleagues [1] entitled
‘The economic costs of diabetes: a population-based study
in Tehran, Iran’. The authors are to be congratulated for
their admirable work in measuring the economic burden of
diabetes, a disease for which the number of people affected
is growing rapidly in developing countries [2]. With
reference to the article, we wish to comment on the
growing burden of diabetes—especially in the context of
developing countries—and then go on to make some
recommendations.
It is estimated that the total number of people with
diabetes globally will rise from 171 million in the year
2000 to more than 366 million in 2030 [2]. Diabetes is a
complex metabolic disorder involving many body organs
and systems and can devastate the lives of affected
individuals. People with diabetes are up to four times more
likely to develop cardiovascular diseases, and up to 40
times more likely to require lower limb amputation, than
people without diabetes [3]. Furthermore, diabetes is among
the leading causes of visual impairment, blindness and
kidney failure in adults [3]. Diabetes is the fourth leading
cause of death by diseases worldwide; more than one
million people died from diabetes in 2005 and almost 80%
of these deaths occurred in low- and middle-income
countries [3, 4]. Due to the premature disability, morbidity
and mortality associated with diabetes, diabetes is one of
the most costly diseases to manage [5, 6]. This burden is
even more of a problem in developing countries where
diabetes and associated cardiovascular diseases develop at
earlier ages and with greater severity [7]. The majority of
people with diabetes in developing countries are below
64 years of age, whereas in developed countries most are in
older age groups [2]. This early onset of diabetes in the
more economically productive years of life leads to a
devastating extra burden of cost in developing countries.
This not only puts extra pressure on individuals, but affects
families, society, and the healthcare system of the country.
Esteghamati and colleagues [1] determined the annual
economic cost of individuals with diabetes in Iran. They
reported significantly higher direct and indirect costs of
diabetes compared with the control group. Moreover, the
authors identified medications and devices as the most
expensive component of direct costs. These results are
consistent with other researchers’ findings and estimates
from developing countries [5, 6]. Nevertheless, we are
concerned that these results may underestimate the eco-
nomic cost of diabetes in Iran.
However, some of the methods used by Esteghamati and
colleagues [1] are either imprecise or misleading. First, the
control group includes people with hypertension and
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dyslipidaemia: these conditions have adverse cost and
resource implications. In this way the authors have
exaggerated the cost of the population group without
diabetes, thereby reducing the comparative cost of people
with diabetes. Second, the authors only estimated produc-
tivity losses for people with diabetes who are economically
active; hence, it would appear that many people with
diabetes have been excluded from the estimates—including
housewives, students and retired people. Moreover, the age
range of the study participants was from 0 to 104 years, so
includes two extreme age groups comprising economically
non-productive segments of the population. Yet no expla-
nation is given as to how this aspect of the analysis was
conducted. Third, patients’ out-of-pocket expenses should
be treated as direct costs, as with visits to healthcare
providers [8]. However, while people with diabetes are
likely to incur significant direct non-healthcare costs [5], in
the study by Esteghamati and colleagues [1] this cost is
treated as an indirect cost. Fourth, although healthcare in
Iran is subsidised by the government [9], the estimation of
healthcare costs in the study appears to have been based on
insurance and out-of-pocket expenditures, with no adjust-
ment indicated for any disparity between prices and the real
costs of healthcare interventions. Finally, the loss of
economic productivity from attendants accompanying
patients is not calculated: many attendants will be econom-
ically active and so not taking their lost productivity into
account may underestimate the economic cost of diabetes.
If all these underestimated costs are taken into consider-
ation, the actual economic cost will be much higher for
people with diabetes relative to those without diabetes.
The existing scenario is one of a projected increase in the
prevalence of diabetes for developing countries, where a
large proportion of people are living below the poverty line
and are dependent on fragile healthcare systems with
limited resources. Prevention is the best option to tackle
this costly epidemic. Preventive interventions should be
available at all levels, with integrated, comprehensive,
multi-faceted and multi-sectoral approaches. In this regard,
activities should be aimed at preventing diabetes from
occurring in susceptible individuals and populations
through prevention and modification of environmental and
behavioural risk factors and determinants. Because diabetes
emerges rapidly in young people, special interventions
should be planned and implemented at schools and colleges
to target children and adolescents in developing countries.
Activities such as early screening for diabetes (aiming at
early detection), and prompt and effective management of
the disease, should be designed with the purpose of
preventing and delaying the onset of complications. Efforts
should also be made to delay onset of the premature
disabilities and the deaths associated with secondary
complications of diabetes. Furthermore, improved standards
of care and management of diabetes in the healthcare
systems of developing countries would particularly help to
ensure that all persons with diabetes have easier access to
high-quality management of their disease at an affordable
cost.
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